5-alpha reductase

(redirected from 5 alpha-reductase)

5-alpha reductase

(al'fa re-duk'tās),
Intracellular enzyme that converts testosterone to 5-alpha dihydrotestosterone (DHT). Two distinct isoforms are known in humans and laboratory animals.

5-alpha reductase

An enzyme that converts testosterone to dihydrotestosterone.
See also: reductase
References in periodicals archive ?
A 5 alpha-reductase enzyme inhibitor, Dutasterid, works by reducing production of a hormone called dihydrotestosterone (DHT).
The company said dutasteride is a 5 alpha-reductase enzyme inhibitor and works by lowering production of a hormone called dihydrotestosterone (DHT).
PURPOSE: We reviewed the physiological and pathogenic role of dihydrotestosterone (DHT), evidence for the beneficial effects of decreasing DHT through 5 alpha-reductase inhibition and the effects of altering the androgen balance with these agents.
The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases.
Prostatic effects induced in dogs by chronic or acute oral administration of 5 alpha-reductase inhibitors.
Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
Differential expression of 5 alpha-reductase isoenzymes in the human prostate and prostatic carcinomas.
The Food and Drug Administration has approved Avodart, the first dual-acting 5 alpha-reductase inhibitor for benign prostatic hyperplasia.
Finasteride belongs to a class of Type II 5 alpha-reductase inhibitors used in the treatment of enlarged prostate glands.
Finasteride is a type II 5 alpha-reductase inhibitor (5-ARI) approved by the FDA for the treatment of BPH in men with an enlarged prostate.